Increased circulating free fatty acids (FFAs) have been proposed to contribute to insulin resistance in obesity. Short-term studies have investigated the effects of acipimox, an inhibitor of hormone-sensitive lipase, on glucose homeostasis, but longer-term studies have not been performed. This study examined the hypothesis that long-term treatment with acipimox would reduce FFA and improve insulin sensitivity among nondiabetic, insulin-resistant, obese subjects.
- Makimura H, Stanley TL, Suresh C, De Sousa-Coelho AL, Frontera WR, Syu S, Braun LR, Looby SE, Feldpausch MN, Torriani M, Lee H, Patti ME, Grinspoon SK. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial. J Clin Endocrinol Metab. 2016 Mar;101(3):1123-33. PMID: 26691888; PMCID: PMC4803166.
Read More: The Journal of Clinical Endocrinology & Metabolism
- Research Center: Harvard Medical School
- Center Contribution: With the help of a Pilot and Feasibility Grant, NORC investigators from Harvard demonstrated that chronic reduction in free fatty acids with acipomox in obese adults with insulin resistance improved fasting glycemia and significantly increased adiponectin but did not affect mitochondrial function or mitochondrial density.